Vivro Financial Services Pvt Ltd ("Manager to the Open Offer") has submitted to BSE a copy of Letter of Offer for the attention of the Equity Shareholders of Rekvina Laboratories Ltd ("''Target ....
M&A
● No Immediate Change
LOW RISK
📅 Filed on BSE: 23 Jun 2026, 01:39 PM IST · BSE ID: 96758786-7d3a-4702-b77f-cc003d280e09
View Original BSE Filing (PDF)
💡
In Simple Terms
Three individuals are making a public offer to buy 28,90,100 shares of Rekvina Laboratories at ₹10 per share.
🤖 AI Summary
- Open offer for Rekvina Laboratories Ltd to acquire up to 28,90,100 equity shares has been launched.
- Three acquirers (Surbhit Mukesh Shah, Amit Mukesh Shah, Dhruvalkumar Patel) are making the offer.
- Offer price is ₹10 per equity share, payable in cash, for 26% of the expanded share capital.
- The open offer period is from Wednesday, July 1, 2026, to Tuesday, July 14, 2026.
🔢 Key Numbers — exact figures from BSE filing, not rounded
Number of Equity Shares to Acquire
28,90,100
Percentage of Expanded Share Capital
26%
Offer Price per Equity Share
₹10/-
Face Value per Equity Share
₹5/-
🏢 How This Affects the Company
Shareholders' tender decisions could alter the company's public shareholding structure after the open offer completion.
👥 What This Means For Shareholders
✅
Action Required
Public shareholders who wish to tender their shares must review the Letter of Offer and submit the Form of Acceptance between July 1, 2026, and July 14, 2026.
👤
Who Is Affected
Public shareholders of Rekvina Laboratories Ltd are affected, as the acquirers are offering to purchase up to 28,90,100 fully paid-up equity shares of face value ₹5/- each from them.
🔍
Management Signal
The offer, made by individuals identified as acquirers, indicates a formal process to increase their stake or consolidate control in Rekvina Laboratories Ltd.
For information only. Not investment advice. ForgeUp is not SEBI-registered.
👁 Watch List — track these upcoming events
Final shareholding post open offer closure on July 14, 2026.
Outcome of any potential revision to the offer price before the tendering period.
Any further disclosures regarding statutory approvals mentioned in the LOF.
LOW RISK
This filing is a standard regulatory step for an open offer, with no immediate adverse risks disclosed for the company.
💡 Investor Takeaway
An open offer is underway for Rekvina Laboratories Ltd. Acquirers Surbhit Mukesh Shah, Amit Mukesh Shah, and Dhruvalkumar Patel seek to acquire 28,90,100 equity shares at ₹10 per share, representing 26% of expanded share capital. The offer opens July 1, 2026, and closes July 14, 2026.
⚖️ Strengths & Concerns
✅ Positives
- The open offer is not conditional upon any minimum level of acceptance, ensuring transaction proceeds regardless of tendered shares.
⚠️ Concerns
- Shares under lock-in from preferential allotments (other than promoters) are not permitted to be tendered, limiting participation for some shareholders.
📅 Company Track Record
This open offer is in continuation of previous filings from April 2, 2026, and March 24, 2026, which detailed the mandatory open offer for 26% stake (28,90,100 shares) at Rs. 10/share, amounting to Rs. 2.89 Cr, alongside a concurrent Rs. 4.62 Cr preferential allotment.
Based on publicly available historical data. For context only.
❓ Frequently Asked Questions
What is the offer price per share in the Rekvina Laboratories open offer?
The offer price is ₹10/- (Rupees Ten Only) per fully paid-up equity share of Rekvina Laboratories Ltd.
How many shares are being sought in the Rekvina Laboratories open offer?
The open offer aims to acquire up to 28,90,100 (Twenty Eight Lakhs Ninety Thousand One Hundred) fully paid-up equity shares.
What percentage of Rekvina Laboratories' expanded share capital does this open offer represent?
The open offer represents 26% (Twenty Six Percent) of the Expanded Share Capital of Rekvina Laboratories Ltd.
When does the Rekvina Laboratories open offer open and close?
The open offer opens on Wednesday, July 1, 2026, and closes on Tuesday, July 14, 2026.
Questions based on this BSE filing only. For information purposes.